Abzena, an end-to-end integrated contract development and manufacturing organization (CDMO) for antibody drug conjugates (ADCs) and complex biologic molecules, has appointed Matthew Stober as their new CEO. Stober was most recently CEO of therapeutic companies CastleVax and Istari Oncology. Earlier in his career he held executive positions at Merk, GSK, Novartis, and was instrumental in helping lead the operational turn-around of Hospira, resulting in the eventual sale to Pfizer for $17 billi...